background
sporozoit
immun
anim
human
chemoprophylact
cover
chloroquin
cpscq
effici
induc
steril
protect
malaria
human
cpscq
strikingli
effici
immun
radiat
attenu
sporozoit
ra
rais
hypothesi
might
partial
due
cq
chloroquin
establish
antimalari
drug
also
well
known
immun
modul
properti
includ
improv
crosspresent
aim
studi
investig
whether
coadministr
cq
sporozoit
immun
improv
cellular
respons
protect
efficaci
plasmodium
berghei
model
method
number
experi
select
complimentari
p
berghei
murin
model
balbcbyj
mice
perform
first
effect
cq
administr
induct
protect
immun
respons
ra
immun
studi
next
effect
cq
induct
circumsporozoit
cs
proteinspecif
cell
immun
p
berghei
parasit
express
mutant
cs
protein
investig
final
direct
comparison
cpscq
cp
mefloquin
mq
antimalari
littl
known
immun
modul
effect
perform
result
cq
coadminist
immun
grade
number
ra
lead
increas
frequenc
total
memori
cell
cs
proteinspecif
cell
also
parasitespecif
cytokin
product
protect
remain
unalt
replac
cq
mq
cp
immun
result
significantli
reduc
percentag
produc
memori
cell
liver
p
similar
protect
conclus
studi
provid
evid
direct
benefici
effect
cq
induct
sporozoiteinduc
immun
respons
protect
p
berghei
malaria
model
altern
higher
effici
cp
compar
ra
might
explain
indirect
effect
cq
limit
bloodstag
exposur
immun
increas
antigen
exposur
therefor
improv
breadth
immun
respons
whole
sporozoit
immun
approach
chloroquin
chemoprophylaxi
sporozoit
cpscq
radiationattenu
sporozoit
ra
effici
induc
protect
murin
malaria
model
human
cpscq
time
effici
ra
requir
bite
total
versu
mosquito
respect
moreov
longlast
immun
respons
cpscq
immun
studi
mice
healthi
human
volunt
go
togeth
protract
protect
sever
murin
studi
demonstr
essenti
role
cell
sporozoiteinduc
preerythrocyt
immun
gener
cell
preerythrocyt
antigen
requir
crossprim
dendrit
cell
cq
sinc
discoveri
use
wide
success
antimalari
resist
develop
recent
explor
treat
cancer
viral
infect
interestingli
cq
also
shown
enhanc
crosspresent
solubl
antigen
nonrepl
influenza
viru
vitro
moreov
vivo
crossprim
cell
solubl
ovalbumin
effect
cqtreat
compar
untreat
mice
cq
improv
induct
influenzaspecif
cytolyt
cell
mice
human
coadministr
cq
hepat
b
vaccin
booster
significantli
increas
number
virusspecif
cell
studi
base
hypothesi
cq
affect
endosom
acidif
degrad
transport
antigen
cytosol
could
favour
crosspresent
preerythrocyt
plasmodium
antigen
therebi
contribut
effici
induct
immun
respons
protect
cpscq
immun
first
topic
investig
effect
cq
immun
ra
establish
immun
model
reli
cell
respons
thu
potenti
benefit
improv
crosspresent
cell
recogn
immunodomin
circumsporozoit
cs
protein
mediat
protect
immun
therefor
effect
cq
induct
csspecif
cell
immun
p
berghei
parasit
express
mutant
cs
protein
contain
model
siinfekl
b
epitop
investig
next
final
direct
comparison
perform
betweeen
cpscq
cp
mefloquin
mq
antimalari
littl
known
immun
modul
effect
includ
improv
crosspresent
akin
cq
mq
induc
arrest
earli
bloodstag
parasit
without
effect
preerythrocyt
parasit
stage
allow
full
liverstag
develop
brief
exposur
earli
blood
stage
perform
experi
select
complimentari
p
berghei
murin
model
aim
studi
explor
effect
cq
protect
cell
respons
whole
sporozoit
immun
balbcbyj
mice
week
old
purchas
elevagejanvi
le
genest
saint
isl
franc
mous
strain
select
base
extens
experi
strain
malaria
immun
studi
follow
parasit
use
p
berghei
anka
strain
wild
type
parasit
p
berghei
parasit
endogen
cs
gene
replac
modifi
circumsporozoit
gene
express
restrict
siinfekl
sporozoit
obtain
dissect
salivari
gland
infect
femal
anophel
stephensi
mosquito
day
blood
meal
infect
mice
anim
studi
procedur
perform
netherland
approv
ethic
committe
anim
research
radboud
univers
nijmegen
rudec
mice
hous
central
anim
facil
nijmegen
receiv
standard
diet
water
ad
libitum
anim
procedur
unit
state
america
approv
institut
anim
care
use
committe
john
hopkin
univers
protocol
number
follow
nation
institut
health
guidelin
anim
hous
care
immun
schedul
sporozoit
challeng
assess
protect
mice
immun
one
balbcbyj
addit
file
two
three
addit
file
intraven
iv
inject
p
berghei
ra
gammacel
cs
weekli
interv
one
intraderm
inject
p
berghei
cs
ra
addit
file
figur
dose
deescal
ra
immun
perform
order
obtain
suboptim
ra
dose
detect
possibl
benefici
effect
cq
addit
file
ra
experi
rascq
group
receiv
either
cq
prophylaxi
chloroquin
diphosph
sigmaaldrich
day
balbcbyj
baseday
oral
day
baseday
intraperiton
efficaci
prophylact
regimen
establish
pilot
studi
chosen
closest
resembl
human
cpsprotocol
altern
mice
given
two
subcutan
inject
cq
base
h
h
immun
particular
regimen
previous
shown
improv
crosspresent
addit
file
furthermor
mice
cq
mq
prophylaxi
immun
three
time
weekli
interv
intraven
administr
wildtyp
pbspz
cp
immun
addit
file
cp
immun
cq
dilut
pb
mq
dilut
dmsowat
inject
given
oral
consecut
day
dosag
baseday
cq
baseday
mefloquin
hydrochlorid
sigmaaldrich
start
first
day
pbspz
administr
challeng
infect
perform
intraven
inject
sporozoit
around
four
eleven
week
end
cqmq
prophylaxi
giemsastain
blood
smear
screen
parasit
red
blood
cell
everi
day
day
final
day
challeng
protect
defin
absenc
bloodstag
parasit
day
postchalleng
addit
file
b
c
mice
euthan
isofluran
inhal
intraven
inject
unit
heparin
spleen
liver
collect
perfus
liver
ml
pb
cell
suspens
liver
spleen
made
passag
organ
nylon
cell
strainer
bd
labwar
liver
cell
resuspend
percol
ge
healthcar
centrifug
g
min
liver
spleen
erythrocyt
lyse
use
min
incub
ice
lyse
solut
ammonium
chlorid
erythrocyt
lysi
hepat
mononuclear
cell
hmc
splenocyt
resuspend
rpmi
medium
fivecolour
stain
hmc
splenocyt
perform
use
monoclon
antibodi
purchas
biolegend
pacif
blueconjug
anti
peridinin
chlorophyl
protein
percp
conjug
anti
alexa
fluor
anti
fluorescein
isothiocyan
fitc
conjug
allophycocyanin
apc
conjug
briefli
cell
resuspend
cold
assay
buffer
pb
supplement
bovin
serum
albumin
sigmaaldrich
incub
min
monoclon
antibodi
cell
fix
fix
perm
medium
invitrogen
collect
assay
buffer
measur
detect
parasitespecif
cytokin
product
hmc
splenocyt
cellswel
cocultur
complet
rpmi
cultur
medium
presenc
p
berghei
cryopreserv
sporozoit
pbspz
ml
infect
red
blood
cell
pbirbc
ml
exposur
salivari
gland
prepar
uninfect
mosquito
uninfect
red
blood
cell
urbc
ml
use
respect
neg
control
cell
stimul
hour
brefeldin
sigmaaldrich
ad
last
four
hour
final
concentr
posit
control
pma
ngml
ionomycin
sigmaaldrich
ad
simultan
along
brefeldin
cell
harvest
vitro
stimul
stain
monoclon
antibodi
indic
fix
permeabil
cell
stain
peconjug
apcconjug
fix
perm
medium
b
invitrogen
min
flow
cytometri
perform
cyan
adp
beckman
coulter
data
analysi
perform
use
flowjo
softwar
version
tree
star
use
gate
strategi
describ
previous
prior
intraderm
immun
p
berghei
cs
ra
mice
receiv
cell
rascq
group
receiv
cq
treatment
basedayor
expans
siinfekl
cell
liver
spleen
assess
flow
cytometri
ten
day
immun
describ
previous
addit
file
differ
protect
two
group
test
fisher
exact
test
overal
comparison
immun
group
perform
use
kruskalw
test
direct
comparison
two
group
ra
versu
rascq
cpscq
versu
cpsmq
perform
mannwhitney
u
test
analysi
cytokin
product
background
respons
salivari
gland
urbc
subtract
pbspz
pbirbc
respons
respect
individu
mous
statist
analys
perform
use
prism
softwar
version
graphpad
san
diego
ca
pvalu
consid
statist
signific
first
experi
perform
investig
whether
administr
prophylact
regimen
cq
improv
memori
cell
respons
induc
ra
immun
mice
ex
vivo
analysi
show
percentag
cell
effector
memori
phenotyp
tem
liver
fold
higher
day
challeng
immun
compar
mice
p
howev
percentag
tem
cell
similar
ra
versu
rascq
mice
figur
similar
pattern
observ
spleen
threefold
increas
tem
level
p
figur
vitro
reexposur
immun
cell
pbspz
show
high
level
produc
memori
cell
liver
spleen
rasimmun
mice
p
respect
increas
addit
cq
administr
figur
similar
observ
made
hepat
splenic
pluripot
memori
cell
produc
major
contribut
cell
liver
figur
summari
addit
cq
administr
affect
neither
frequenc
rasinduc
tem
cell
sporozoitespecif
cytokin
product
cell
circumsporozoit
cs
protein
establish
target
protein
protect
immun
mice
human
effect
cq
cell
respons
siinfekl
b
restrict
epitop
integr
protein
studi
next
line
result
mice
immun
ra
whilst
cq
cover
show
similar
percentag
hepat
splenic
csspecif
cell
compar
untreat
mice
figur
evalu
potenti
effect
cq
ra
protect
efficaci
group
balbcbyj
mice
immun
grade
number
ra
challeng
monitor
parasitemia
mice
strain
reduct
immun
dose
result
stepwis
decreas
protect
influenc
either
prophylact
regimen
daili
cq
two
low
dose
cq
h
h
immun
tabl
cq
administ
immun
effect
challeng
infect
sinc
control
mice
receiv
cqprophylaxi
show
prepat
period
untreat
mice
next
immun
respons
protect
cpscq
cpsmq
immun
investig
tem
level
figur
product
upon
vitro
restimul
pbspz
pbirbc
pluripot
cell
produc
figur
significantli
increas
immun
compar
control
mice
although
signific
trend
higher
tem
level
cpscq
compar
cpsmq
liver
spleen
p
respect
figur
cell
isol
liver
cpscq
mice
show
higher
respons
vitro
reexposur
pbirbc
p
trend
higher
respons
pbspz
reexposur
p
figur
spleen
similar
trend
higher
respons
cpscq
group
observ
upon
reexposur
pbspz
pbirbc
figur
follow
vitro
reexposur
pbirbc
pbspz
percentag
hepat
pluripot
memori
cell
produc
significantli
higher
cpscq
group
compar
cpsmq
group
p
figur
thu
cpscq
result
somewhat
higher
specif
cytokin
respons
compar
cpsmq
final
mice
challeng
intraven
administr
sporozoit
five
ten
week
second
booster
day
sporozoit
day
day
cpscq
cpsmq
immun
mice
protect
challeng
low
k
high
k
sporozoit
dose
control
mice
includ
cq
mq
prophylaxi
group
develop
bloodstag
parasitaemia
postpon
challeng
day
result
protect
cpscq
cpsmq
group
tabl
altogeth
differ
protect
cp
immun
either
cpscq
cpsmq
although
cellular
respons
whole
sporozoit
immun
cq
cover
increas
addit
cq
p
berghei
ra
immun
protocol
improv
neither
protect
parasitespecif
cell
respons
slightli
reduc
cell
respons
similar
protect
efficaci
found
cpscq
compar
cpsmq
studi
involv
investig
effect
cq
crosspresent
vitro
detail
mechanist
antigen
present
studi
altern
figur
frequenc
siinfekl
specif
cell
follow
ra
immun
cq
cover
prior
ra
intraderm
immun
rascq
without
chloroquin
ra
mice
receiv
inject
siinfeklspecif
cell
ten
day
singl
immun
expans
siinfeklspecif
cell
determin
liver
spleen
immun
group
ns
signific
function
readout
examin
parasitespecif
cell
respons
protect
challeng
infect
assess
potenti
immun
enhanc
effect
cq
combin
p
berghei
data
provid
evid
signific
improv
whole
sporozoit
immun
presenc
cq
therefor
indic
cq
respons
strikingli
higher
effici
cpscq
compar
ra
human
improv
crosspresent
result
increas
product
cell
shown
vitro
studi
dendrit
cell
puls
solubl
viral
antigen
presenc
cq
mice
cq
shown
enhanc
crosspresent
solubl
ova
oti
cell
vitro
vivo
improv
specif
cell
respons
alumova
immun
effect
cq
ova
crosspresent
observ
upon
administr
protein
suggest
immunomodulatori
effect
cq
benefici
suboptim
immun
condit
current
studi
ra
immun
without
cq
induc
strong
cellular
respons
similar
contribut
cell
translat
equal
protect
level
even
downtitr
ra
immun
dose
associ
decreas
protect
clear
improv
cq
remain
undetect
human
singl
administr
cq
hepat
b
booster
vaccin
significantli
improv
cell
respons
despit
sever
report
enhanc
immun
respons
cq
mice
men
one
studi
report
improv
protect
mice
immun
heatinactiv
influenza
viru
show
improv
surviv
rate
challeng
infect
signific
improv
immun
respons
protect
thu
remain
explor
one
assum
improv
crosspresent
cq
applic
solubl
protein
peptid
antigen
present
form
whole
sporozoit
improv
crosspresent
siinfekl
peptid
ova
inactiv
influenza
viru
cq
mice
demonstr
howev
cq
administr
sporozoit
immun
siinfekl
express
p
berghei
sporozoit
show
increas
siinfeklspecif
cell
suggest
present
pathway
effect
cq
might
differ
pathogen
antigen
cpscq
immun
mice
requir
rel
high
lengthi
drug
prophylaxi
prevent
develop
p
berghei
infect
k
nganoumakamdop
unpublish
data
result
cpscq
mice
cumul
receiv
much
cq
two
dose
chloroquin
diphosph
salt
previous
shown
improv
crosspresent
therefor
effect
low
cqdose
regimen
ra
immun
assess
separ
experi
protect
level
higher
compar
ra
alon
indic
choic
cq
dose
crucial
immun
modul
effect
mq
report
includ
crosspresent
formal
exclud
mq
cp
immun
regim
may
similar
properti
cq
cq
mq
lysosomotrop
agent
limit
endosom
acidif
cq
known
result
inhibit
lysosom
enzym
requir
acid
ph
function
fusion
endosom
lysosom
cq
mq
wide
use
studi
role
endosom
acidif
cellular
process
cq
also
studi
extens
inhibitori
effect
autophagi
recent
public
suggest
mq
similar
effect
autophagi
endosom
acidif
autophagi
might
influenc
antigen
present
effect
mq
process
may
result
immun
modul
effect
case
cq
absenc
evid
direct
immunemodul
effect
cq
whole
sporozoit
immun
rule
cq
mq
might
instead
contribut
effici
induct
protect
indirect
way
review
rodent
sporozoit
immun
studi
demonstr
import
optim
exposur
entir
repertoir
liver
stage
antigen
occur
cpscq
cpsmq
reduc
protect
efficaci
liver
stage
develop
halt
drug
case
ra
genet
attenu
parasit
furthermor
report
show
neg
effect
bloodstag
parasit
induc
preerythrocyt
cell
respons
interf
dendrit
cell
function
limit
exposur
blood
stage
cp
immun
cq
mq
might
thu
indirect
posit
effect
preerythrocyt
immun
studi
provid
evid
improv
immun
respons
protect
efficaci
cq
p
berghei
model
instead
higher
effici
cp
compar
ra
human
might
explain
indirect
effect
cq
limit
bloodstag
exposur
immun
improv
breadth
immun
respons
result
increas
antigen
exposur
absenc
clear
immun
enhanc
effect
cq
work
need
assess
whether
find
translat
human
set
addit
file
studi
design
effect
chloroquin
cq
immun
respons
protect
whole
sporozoit
immun
test
number
p
berghei
model
balbcbyj
mice
b
receiv
intraven
iv
immun
radiat
attenu
sporozoit
ra
immun
dose
grey
without
addit
administr
cq
grey
bar
mice
challeng
iv
inject
wild
type
wt
p
berghei
sporozoit
spz
follow
blood
smear
detect
parasit
c
mice
immun
p
berghei
cs
ra
receiv
cell
without
cq
prophylaxi
grey
bar
expans
siinfekl
cell
liver
spleen
assess
flow
cytometri
day
immun
mice
immun
iv
administr
wt
p
berghei
spz
receiv
either
cq
mefloquin
mq
prophylaxi
challeng
day
either
wt
berghei
spz
day
wt
berghei
spz
follow
blood
smear
detect
parasit
